HC Wainwright Brokers Lower Earnings Estimates for Rezolute

Rezolute, Inc. (NASDAQ:RZLT) – Analysts at HC Wainwright decreased their FY2031 earnings per share (EPS) estimates for Rezolute in a report issued on Friday, November 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $2.82 per share for the year, down from their previous estimate of $2.94. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.63) per share.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01.

Other analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Rezolute in a report on Thursday, October 15th. Citigroup reaffirmed a “market outperform” rating on shares of Rezolute in a research report on Thursday, October 15th. Citizens Jmp upped their price objective on shares of Rezolute from $11.00 to $15.00 and gave the company a “market outperform” rating in a research note on Tuesday, October 6th. HSBC upgraded shares of Rezolute to a “buy” rating in a research note on Friday, September 25th. Finally, Lake Street Capital increased their target price on shares of Rezolute from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, October 6th. Twelve equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.22.

Rezolute Stock Down 0.3%

NASDAQ:RZLT opened at $3.87 on Monday. Rezolute has a fifty-two week low of $1.07 and a fifty-two week high of $11.46. The stock’s 50-day moving average is $4.12 and its two-hundred day moving average is $3.91.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Jennison Associates LLC purchased a new stake in shares of Rezolute during the 1st quarter worth about $10,489,000. Siren L.L.C. bought a new stake in shares of Rezolute in the 1st quarter valued at approximately $10,151,000. Dimensional Fund Advisors LP grew its stake in shares of Rezolute by 273.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 530,229 shares of the company’s stock valued at $1,617,000 after buying an additional 388,346 shares in the last quarter. Knott David M Jr increased its holdings in Rezolute by 8.8% in the first quarter. Knott David M Jr now owns 370,000 shares of the company’s stock worth $1,128,000 after buying an additional 30,000 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Rezolute in the second quarter worth approximately $1,104,000. 82.97% of the stock is owned by institutional investors and hedge funds.

Rezolute Company Profile

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases involving abnormal insulin activity. The company’s lead product candidate is RZ358, also known as ersodetug, an investigational monoclonal antibody designed to reduce the effects of excessive insulin by binding to an allosteric site on the insulin receptor.

RZ358 is being developed primarily for the treatment of congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin, causing potentially severe and recurrent hypoglycemia.